Carrie E Bearden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6471138/publications.pdf Version: 2024-02-01



CADDIE E READDEN

#	Article	IF	CITATIONS
1	Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes. Psychological Medicine, 2023, 53, 3644-3651.	2.7	5
2	Intelligence, educational attainment, and brain structure in those at familial highâ€risk for schizophrenia or bipolar disorder. Human Brain Mapping, 2022, 43, 414-430.	1.9	14
3	Intracranial and subcortical volumes in adolescents with <scp>earlyâ€onset</scp> psychosis: A multisite <scp>megaâ€analysis</scp> from the <scp>ENIGMA</scp> consortium. Human Brain Mapping, 2022, 43, 373-384.	1.9	27
4	What we learn about bipolar disorder from largeâ€scale neuroimaging: Findings and future directions from the <scp>ENIGMA</scp> Bipolar Disorder Working Group. Human Brain Mapping, 2022, 43, 56-82.	1.9	67
5	ENICMAâ€ÐTI: Translating reproducible white matter deficits into personalized vulnerability metrics in crossâ€diagnostic psychiatric research. Human Brain Mapping, 2022, 43, 194-206.	1.9	52
6	North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophrenia Research, 2022, 243, 262-267.	1.1	39
7	Effects of copy number variations on brain structure and risk for psychiatric illness: Largeâ€scale studies from the <scp>ENIGMA</scp> working groups on <scp>CNVs</scp> . Human Brain Mapping, 2022, 43, 300-328.	1.9	30
8	A normative chart for cognitive development in a genetically selected population. Neuropsychopharmacology, 2022, 47, 1379-1386.	2.8	12
9	Life Event Stress and Reduced Cortical Thickness in Youth at Clinical High Risk for Psychosis and Healthy Control Subjects. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 171-179.	1.1	2
10	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 111-121.	2.3	15
11	Individualized Prediction of Prodromal Symptom Remission for Youth at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 395-404.	2.3	7
12	The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity. Neuropsychopharmacology, 2022, 47, 628-640.	2.8	29
13	Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 1379-1388.	1.6	4
14	The associations between area-level residential instability and gray matter volumes from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2022, 241, 1-9.	1.1	8
15	Cross disorder comparisons of brain structure in schizophrenia, bipolar disorder, major depressive disorder, and 22q11.2 deletion syndrome: A review of <scp>ENIGMA</scp> findings. Psychiatry and Clinical Neurosciences, 2022, 76, 140-161.	1.0	27
16	Longitudinal impact of trauma in the North American Prodrome Longitudinal Studyâ€3. Microbial Biotechnology, 2022, 16, 1211-1216.	0.9	0
17	Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology. American Journal of Psychiatry, 2022, 179, 189-203.	4.0	29
18	Family history of psychosis in youth at clinical high risk: A replication study. Psychiatry Research, 2022, 311, 114480.	1.7	3

#	Article	IF	CITATIONS
19	Neurobehavioral Dimensions of Prader Willi Syndrome: Relationships Between Sleep and Psychosis-Risk Symptoms. Frontiers in Psychiatry, 2022, 13, 868536.	1.3	4
20	App-enhanced transdiagnostic CBT for adolescents with mood or psychotic spectrum disorders. Journal of Affective Disorders, 2022, 311, 319-326.	2.0	8
21	Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis. JAMA Psychiatry, 2022, 79, 780.	6.0	21
22	The Association Between Neighborhood Poverty and Hippocampal Volume Among Individuals at Clinical High-Risk for Psychosis: The Moderating Role of Social Engagement. Schizophrenia Bulletin, 2022, 48, 1032-1042.	2.3	9
23	Copy number variation at the 22q11.2 locus influences prevalence, severity, and psychiatric impact of sleep disturbance. Journal of Neurodevelopmental Disorders, 2022, 14, .	1.5	8
24	Associations between childhood adversity, cognitive schemas and attenuated psychotic symptoms. Microbial Biotechnology, 2021, 15, 818-827.	0.9	10
25	Genome-wide mapping of brain phenotypes in extended pedigrees with strong genetic loading for bipolar disorder. Molecular Psychiatry, 2021, 26, 5229-5238.	4.1	4
26	Cross-paradigm connectivity: reliability, stability, and utility. Brain Imaging and Behavior, 2021, 15, 614-629.	1.1	7
27	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 2021, 227, 10-17.	1.1	28
28	Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. Microbial Biotechnology, 2021, 15, 96-103.	0.9	9
29	Childhood trauma and cognitive functioning in individuals at clinical high risk (CHR) for psychosis. Development and Psychopathology, 2021, 33, 53-64.	1.4	5
30	Depression: An actionable outcome for those at clinical high-risk. Schizophrenia Research, 2021, 227, 38-43.	1.1	7
31	Social decline in the psychosis prodrome: Predictor potential and heterogeneity of outcome. Schizophrenia Research, 2021, 227, 44-51.	1.1	12
32	Concordance and factor structure of subthreshold positive symptoms in youth at clinical high risk for psychosis. Schizophrenia Research, 2021, 227, 72-77.	1.1	4
33	Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis. Schizophrenia Research, 2021, 227, 95-100.	1.1	17
34	Genetic analysis of activity, brain and behavioral associations in extended families with heavy genetic loading for bipolar disorder. Psychological Medicine, 2021, 51, 494-502.	2.7	6
35	Discriminatory experiences predict neuroanatomical changes and anxiety among healthy individuals and those at clinical high risk for psychosis. NeuroImage: Clinical, 2021, 31, 102757.	1.4	8
36	A Genetics-First Approach to Dissecting the Heterogeneity of Autism: Phenotypic Comparison of Autism Risk Copy Number Variants. American Journal of Psychiatry, 2021, 178, 77-86.	4.0	62

#	Article	IF	CITATIONS
37	Risk and Resilience in Extraordinary Times. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 136-138.	1.1	1
38	Prioritizing Genetic Contributors to Cortical Alterations in 22q11.2 Deletion Syndrome Using Imaging Transcriptomics. Cerebral Cortex, 2021, 31, 3285-3298.	1.6	10
39	Abnormally Large Baseline P300 Amplitude Is Associated With Conversion to Psychosis in Clinical High Risk Individuals With a History of Autism: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 591127.	1.3	10
40	Social cognition in 22q11.2 deletion syndrome and idiopathic developmental neuropsychiatric disorders. Journal of Neurodevelopmental Disorders, 2021, 13, 15.	1.5	13
41	Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study. Schizophrenia Research, 2021, 230, 26-37.	1.1	4
42	White matter changes in psychosis risk relate to development and are not impacted by the transition to psychosis. Molecular Psychiatry, 2021, 26, 6833-6844.	4.1	15
43	Neurocognitive subprocesses of working memory performance. Cognitive, Affective and Behavioral Neuroscience, 2021, 21, 1130-1152.	1.0	8
44	Structural and functional brain alterations revealed by neuroimaging in CNV carriers. Current Opinion in Genetics and Development, 2021, 68, 88-98.	1.5	14
45	Inter-rater reliability of subthreshold psychotic symptoms in individuals with 22q11.2 deletion syndrome. Journal of Neurodevelopmental Disorders, 2021, 13, 23.	1.5	1
46	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	0.7	32
47	Effects of eight neuropsychiatric copy number variants on human brain structure. Translational Psychiatry, 2021, 11, 399.	2.4	18
48	Mitochondrial Proteostasis Requires Genes Encoded in a Neurodevelopmental Syndrome Locus. Journal of Neuroscience, 2021, 41, 6596-6616.	1.7	18
49	Harnessing rare variants in neuropsychiatric and neurodevelopment disorders—a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, , .	1.8	2
50	Familyâ€focused therapy for individuals at high clinical risk for psychosis: A confirmatory efficacy trial. Microbial Biotechnology, 2021, , .	0.9	1
51	Anxiety in youth at clinical high-risk for psychosis: A two-year follow-up. Schizophrenia Research, 2021, 236, 87-88.	1.1	1
52	Genetic and clinical analyses of psychosis spectrum symptoms in a large multiethnic youth cohort reveal significant link with ADHD. Translational Psychiatry, 2021, 11, 80.	2.4	11
53	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	4.1	87
54	Heterotopia in Individuals with 22q11.2 Deletion Syndrome. American Journal of Neuroradiology, 2021, 42, 2070-2076.	1.2	3

#	Article	IF	CITATIONS
55	Confident memory errors and disrupted reality testing in early psychosis. Schizophrenia Research, 2021, 238, 170-177.	1.1	4
56	Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2021, 238, 137-144.	1.1	7
57	Transcriptomic profiling of whole blood in 22q11.2 reciprocal copy number variants reveals that cell proportion highly impacts gene expression. Brain, Behavior, & Immunity - Health, 2021, 18, 100386.	1.3	3
58	Opposing white matter microstructure abnormalities in 22q11.2 deletion and duplication carriers. Translational Psychiatry, 2021, 11, 580.	2.4	4
59	Depression Predicts Global Functional Outcomes in Individuals at Clinical High Risk for Psychosis. Psychiatric Research and Clinical Practice, 2021, 3, 163-171.	1.3	4
60	State-Dependent Functional Dysconnectivity in Youth With Psychosis Spectrum Symptoms. Schizophrenia Bulletin, 2020, 46, 408-421.	2.3	9
61	Progressive reconfiguration of resting-state brain networks as psychosis develops: Preliminary results from the North American Prodrome Longitudinal Study (NAPLS) consortium. Schizophrenia Research, 2020, 226, 30-37.	1.1	36
62	Stress perception following childhood adversity: Unique associations with adversity type and sex. Development and Psychopathology, 2020, 32, 343-356.	1.4	25
63	Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. Molecular Psychiatry, 2020, 25, 1822-1834.	4.1	122
64	Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains. American Journal of Psychiatry, 2020, 177, 164-171.	4.0	34
65	Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study. Molecular Psychiatry, 2020, 25, 2818-2831.	4.1	50
66	Synaptic and Gene Regulatory Mechanisms in Schizophrenia, Autism, and 22q11.2 Copy Number Variant–Mediated Risk for Neuropsychiatric Disorders. Biological Psychiatry, 2020, 87, 150-163.	0.7	46
67	Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk. American Journal of Psychiatry, 2020, 177, 155-163.	4.0	90
68	Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects. American Journal of Human Genetics, 2020, 106, 26-40.	2.6	42
69	Psychosis Risk and Development: What Do We Know From Population-Based Studies?. Biological Psychiatry, 2020, 88, 315-325.	0.7	21
70	Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophrenia Research, 2020, 216, 184-191.	1.1	22
71	Applying a Transdiagnostic Cognitive-Behavioral Treatment to Adolescents at High Risk for Serious Mental Illness: Rationale and Preliminary Findings. Cognitive and Behavioral Practice, 2020, 27, 202-214.	0.9	22
72	Duration of the psychosis prodrome. Schizophrenia Research, 2020, 216, 443-449.	1.1	16

#	Article	IF	CITATIONS
73	T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S274-S275.	2.3	0
74	M155. RECIPROCAL CHANGES IN WHITE MATTER MICROSTRUCTURE IN 22Q11.2 DELETION AND DUPLICATION SYNDROME. Schizophrenia Bulletin, 2020, 46, S194-S195.	2.3	0
75	S81. METAMEMORY IMPAIRMENT ACROSS THE PSYCHOSIS TRAJECTORY: ASSOCIATIONS WITH SYMPTOM SEVERITY. Schizophrenia Bulletin, 2020, 46, S65-S65.	2.3	0
76	Mutations associated with neuropsychiatric conditions delineate functional brain connectivity dimensions contributing to autism and schizophrenia. Nature Communications, 2020, 11, 5272.	5.8	35
77	Evidence of Slow Neural Processing, Developmental Differences and Sensitivity to Cannabis Effects in a Sample at Clinical High Risk for Psychosis From the NAPLS Consortium Assessed With the Human Startle Paradigm. Frontiers in Psychiatry, 2020, 11, 833.	1.3	4
78	Relationships between intrinsic functional connectivity, cognitive control, and reading achievement across development. NeuroImage, 2020, 221, 117202.	2.1	13
79	A Review of Default Mode Network Connectivity and Its Association With Social Cognition in Adolescents With Autism Spectrum Disorder and Early-Onset Psychosis. Frontiers in Psychiatry, 2020, 11, 614.	1.3	50
80	Distinct and shared contributions of diagnosis and symptom domains to cognitive performance in severe mental illness in the Paisa population: a case-control study. Lancet Psychiatry,the, 2020, 7, 411-419.	3.7	24
81	Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study. Clinical Neurophysiology, 2020, 131, 2899-2909.	0.7	6
82	Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nature Medicine, 2020, 26, 1912-1918.	15.2	90
83	Patterns of Cortical Folding Associated with Autistic Symptoms in Carriers and Noncarriers of the 22q11.2 Microdeletion. Cerebral Cortex, 2020, 30, 5281-5292.	1.6	3
84	Language as a biomarker for psychosis: A natural language processing approach. Schizophrenia Research, 2020, 226, 158-166.	1.1	86
85	ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. Translational Psychiatry, 2020, 10, 100.	2.4	365
86	Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort. Psychoneuroendocrinology, 2020, 115, 104649.	1.3	21
87	Neuroanatomical underpinnings of autism symptomatology in carriers and non-carriers of the 22q11.2 microdeletion. Molecular Autism, 2020, 11, 46.	2.6	8
88	Stability of mismatch negativity eventâ€related potentials in a multisite study. International Journal of Methods in Psychiatric Research, 2020, 29, e1819.	1.1	10
89	Extensions of Multiple-Group Item Response Theory Alignment: Application to Psychiatric Phenotypes in an International Genomics Consortium. Educational and Psychological Measurement, 2020, 80, 870-909.	1.2	12
90	Contribution of common and rare variants to bipolar disorder susceptibility in extended pedigrees from population isolates. Translational Psychiatry, 2020, 10, 74.	2.4	25

#	Article	IF	CITATIONS
91	Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. American Journal of Psychiatry, 2020, 177, 589-600.	4.0	55
92	Reciprocal Copy Number Variations at 22q11.2 Produce Distinct and Convergent Neurobehavioral Impairments Relevant for Schizophrenia and Autism Spectrum Disorder. Biological Psychiatry, 2020, 88, 260-272.	0.7	35
93	Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis Journal of Abnormal Psychology, 2020, 129, 599-611.	2.0	15
94	Neuronal defects in a human cellular model of 22q11.2 deletion syndrome. Nature Medicine, 2020, 26, 1888-1898.	15.2	113
95	O5.6. ADVANCED DIFFUSION IMAGING IN PSYCHOSIS RISK: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF WHITE MATTER DEVELOPMENT. Schizophrenia Bulletin, 2020, 46, S13-S13.	2.3	0
96	Social vs. non-social measures of learning potential for predicting community functioning across phase of illness in schizophrenia. Schizophrenia Research, 2019, 204, 104-110.	1.1	6
97	Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome. Schizophrenia Research, 2019, 204, 320-325.	1.1	19
98	Neurocognitive profiles in the prodrome to psychosis in NAPLS-1. Schizophrenia Research, 2019, 204, 311-319.	1.1	30
99	Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. JAMA Psychiatry, 2019, 76, 1187.	6.0	59
100	Mechanisms underlying the EEG biomarker in Dup15q syndrome. Molecular Autism, 2019, 10, 29.	2.6	31
101	Accelerating the Bending Arc Toward Equality: A Commentary on Gender Trends in Authorship in Psychiatry Journals. Biological Psychiatry, 2019, 86, 575-576.	0.7	4
102	Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. Psychiatry Research, 2019, 282, 112492.	1.7	24
103	A framework for the investigation of rare genetic disorders in neuropsychiatry. Nature Medicine, 2019, 25, 1477-1487.	15.2	90
104	Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. NeuroImage: Clinical, 2019, 23, 101862.	1.4	48
105	The Association Between Familial Risk and Brain Abnormalities Is Disease Specific: An ENIGMA-Relatives Study of Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2019, 86, 545-556.	0.7	67
106	Systems Analysis of the 22q11.2 Microdeletion Syndrome Converges on a Mitochondrial Interactome Necessary for Synapse Function and Behavior. Journal of Neuroscience, 2019, 39, 1983-18.	1.7	38
107	Clinical Profiles and Conversion Rates Among Young Individuals With Autism Spectrum Disorder Who Present to Clinical High Risk for Psychosis Services. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 582-588.	0.3	38
108	Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis. Schizophrenia Research, 2019, 213, 48-55.	1.1	21

#	Article	IF	CITATIONS
109	The Early Psychosis Screener for Internet (EPSI)-SR: Predicting 12â€ ⁻ month psychotic conversion using machine learning. Schizophrenia Research, 2019, 208, 390-396.	1.1	13
110	Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study. Schizophrenia Research, 2019, 208, 41-43.	1.1	15
111	Reduced higher dimensional temporal dynamism in neurofibromatosis type 1. NeuroImage: Clinical, 2019, 22, 101692.	1.4	3
112	Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. Psychological Medicine, 2019, 49, 1670-1677.	2.7	74
113	Altered Brain Activation During Memory Retrieval Precedes and Predicts Conversion to Psychosis in Individuals at Clinical High Risk. Schizophrenia Bulletin, 2019, 45, 924-933.	2.3	14
114	Disruptions in White Matter Maturation and Mediation of Cognitive Development in Youths on the Psychosis Spectrum. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 423-433.	1.1	6
115	Structural Brain Alterations in Youth With Psychosis and Bipolar Spectrum Symptoms. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 1079-1091.	0.3	26
116	The Global Functioning: Social and Role Scales—Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2019, 45, 763-772.	2.3	55
117	Tobacco use and psychosis risk in persons at clinical high risk. Microbial Biotechnology, 2019, 13, 1173-1181.	0.9	11
118	Dissociable Disruptions in Thalamic and Hippocampal Resting-State Functional Connectivity in Youth with 22q11.2 Deletions. Journal of Neuroscience, 2019, 39, 1301-1319.	1.7	31
119	Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain, Behavior, and Immunity, 2019, 76, 268-274.	2.0	48
120	Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. Schizophrenia Research, 2019, 204, 96-103.	1.1	31
121	The role of a family history of psychosis for youth at clinical high risk of psychosis. Microbial Biotechnology, 2019, 13, 251-256.	0.9	10
122	Changes in symptom content from a clinical highâ€risk state to conversion to psychosis. Microbial Biotechnology, 2019, 13, 257-263.	0.9	7
123	Toward Leveraging Human Connectomic Data in Large Consortia: Generalizability of fMRI-Based Brain Graphs Across Sites, Sessions, and Paradigms. Cerebral Cortex, 2019, 29, 1263-1279.	1.6	55
124	The Early Psychosis Screener (EPS): Quantitative validation against the SIPS using machine learning. Schizophrenia Research, 2018, 197, 516-521.	1.1	11
125	Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. Schizophrenia Bulletin, 2018, 44, 254-263.	2.3	51
126	Getting Off Tract: Developmental Disruptions of White Matter in Youth With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 82-83.	0.3	0

#	Article	IF	CITATIONS
127	Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2. Human Molecular Genetics, 2018, 27, 1150-1163.	1.4	22
128	Prediction of psychosis across protocols and risk cohorts using automated language analysis. World Psychiatry, 2018, 17, 67-75.	4.8	264
129	Latent class cluster analysis of symptom ratings identifies distinct subgroups within the clinical high risk for psychosis syndrome. Schizophrenia Research, 2018, 197, 522-530.	1.1	22
130	Enhanced switching and familial susceptibility for psychosis. Brain and Behavior, 2018, 8, e00988.	1.0	0
131	Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. Journal of Clinical Child and Adolescent Psychology, 2018, 47, 69-78.	2.2	17
132	Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophrenia Research, 2018, 192, 357-363.	1.1	45
133	Potentially important periods of change in the development of social and role functioning in youth at clinical high risk for psychosis. Development and Psychopathology, 2018, 30, 39-47.	1.4	31
134	Episodic Memory for Dynamic Social Interaction Across Phase of Illness in Schizophrenia. Schizophrenia Bulletin, 2018, 44, 620-630.	2.3	6
135	Exploration of clinical high-risk dropouts. Schizophrenia Research, 2018, 195, 579-580.	1.1	15
136	The many roads to psychosis: recent advances in understanding risk and mechanisms. F1000Research, 2018, 7, 1883.	0.8	14
137	Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. American Journal of Medical Genetics, Part A, 2018, 176, 2172-2181.	0.7	33
138	Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. Nature Communications, 2018, 9, 3836.	5.8	156
139	Understanding the Hidden Complexity of Latin American Population Isolates. American Journal of Human Genetics, 2018, 103, 707-726.	2.6	48
140	Connectivity-enhanced diffusion analysis reveals white matter density disruptions in first episode and chronic schizophrenia. NeuroImage: Clinical, 2018, 18, 608-616.	1.4	40
141	Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at Clinically High Risk. JAMA Psychiatry, 2018, 75, 960.	6.0	114
142	The relation of atypical antipsychotic use and stress with weight in individuals at clinical high risk for psychosis. Stress and Health, 2018, 34, 591-600.	1.4	3
143	Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study. Schizophrenia Research, 2018, 201, 130-136.	1.1	13
144	Networks of blood proteins in the neuroimmunology of schizophrenia. Translational Psychiatry, 2018, 8, 112.	2.4	16

#	Article	IF	CITATIONS
145	Alternative diffusion anisotropy measures for the investigation of white matter alterations in 22q11.2 deletion syndrome. , 2018, , .		3
146	ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwide. NeuroImage, 2017, 145, 389-408.	2.1	173
147	Anxiety in youth at clinical high risk for psychosis. Microbial Biotechnology, 2017, 11, 480-487.	0.9	56
148	Risky Decision Making in Neurofibromatosis Type 1: An Exploratory Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 170-179.	1.1	2
149	PEMapper and PECaller provide a simplified approach to whole-genome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1923-E1932.	3.3	31
150	Ventricular enlargement and progressive reduction of cortical gray matter are linked in prodromal youth who develop psychosis. Schizophrenia Research, 2017, 189, 169-174.	1.1	32
151	Increased hippocampal, thalamus and amygdala volume in longâ€ŧerm lithiumâ€ŧreated bipolar I disorder patients compared with unmedicated patients and healthy subjects. Bipolar Disorders, 2017, 19, 41-49.	1.1	63
152	The Role of microRNA Expression in Cortical Development During Conversion to Psychosis. Neuropsychopharmacology, 2017, 42, 2188-2195.	2.8	12
153	Emerging Global Initiatives in Neurogenetics: The Enhancing Neuroimaging Genetics through Meta-analysis (ENIGMA) Consortium. Neuron, 2017, 94, 232-236.	3.8	67
154	Multisite reliability of MR-based functional connectivity. NeuroImage, 2017, 146, 959-970.	2.1	140
155	Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study. Schizophrenia Bulletin, 2017, 43, 1079-1089.	2.3	47
156	Mapping 22q11.2 Gene Dosage Effects on Brain Morphometry. Journal of Neuroscience, 2017, 37, 6183-6199.	1.7	65
157	Intrinsic Connectivity Network-Based Classification and Detection of Psychotic Symptoms in Youth With 22q11.2 Deletions. Cerebral Cortex, 2017, 27, 3294-3306.	1.6	18
158	Comorbid diagnoses for youth at clinical high risk of psychosis. Schizophrenia Research, 2017, 190, 90-95.	1.1	95
159	Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. Psychiatry Research, 2017, 258, 462-468.	1.7	6
160	Genome-Wide Association Study to Find Modifiers for Tetralogy of Fallot in the 22q11.2 Deletion Syndrome Identifies Variants in the <i>GPR98</i> Locus on 5q14.3. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	22
161	Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2017, 174, 1054-1063.	4.0	77
162	A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium. Molecular Psychiatry, 2017, 22, 1664-1672.	4.1	65

#	Article	IF	CITATIONS
163	Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity. NeuroImage: Clinical, 2017, 15, 801-811.	1.4	22
164	Enhancing the Informativeness and Replicability of Imaging Genomics Studies. Biological Psychiatry, 2017, 82, 157-164.	0.7	48
165	Categorical Versus Dimensional Approaches to Autism-Associated Intermediate Phenotypes in 22q11.2 Microdeletion Syndrome. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 53-65.	1.1	15
166	Disrupted Working Memory Circuitry in Adolescent Psychosis. Frontiers in Human Neuroscience, 2017, 11, 394.	1.0	4
167	SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2017, 43, S207-S208.	2.3	4
168	Cognitive genomics: Searching for the genetic roots of neuropsychological functioning Neuropsychology, 2017, 31, 1003-1019.	1.0	15
169	Reverse Pathway Genetic Approach Identifies Epistasis in Autism Spectrum Disorders. PLoS Genetics, 2017, 13, e1006516.	1.5	38
170	Characterization of Expression Quantitative Trait Loci in Pedigrees from Colombia and Costa Rica Ascertained for Bipolar Disorder. PLoS Genetics, 2016, 12, e1006046.	1.5	4
171	An Individualized Risk Calculator for Research in Prodromal Psychosis. American Journal of Psychiatry, 2016, 173, 980-988.	4.0	458
172	Cognitive Phenotypes and Endophenotypes: Concepts and Criteria. Innovations in Cognitive Neuroscience, 2016, , 61-80.	0.3	0
173	Insights into psychosis risk from leukocyte microRNA expression. Translational Psychiatry, 2016, 6, e981-e981.	2.4	29
174	Biotypes: The Tip of the Research Domain Criteria Iceberg. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 486-487.	1.1	1
175	Early interventions in risk groups for schizophrenia: what are we waiting for?. NPJ Schizophrenia, 2016, 2, 16003.	2.0	111
176	The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. Schizophrenia Research, 2016, 172, 29-34.	1.1	15
177	Electrophysiological Endophenotypes for Schizophrenia. Harvard Review of Psychiatry, 2016, 24, 129-147.	0.9	37
178	Traumatic brain injury in individuals at clinical high risk for psychosis. Schizophrenia Research, 2016, 174, 77-81.	1.1	12
179	Core Schemas in Youth at Clinical High Risk for Psychosis. Behavioural and Cognitive Psychotherapy, 2016, 44, 203-213.	0.9	25
180	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophrenia Bulletin, 2016, 42, 1234-1242.	2.3	17

#	Article	IF	CITATIONS
181	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	0.7	2
182	Molecular Architecture andÂNeurobiology of Bipolar Disorder. , 2016, , 467-486.		2
183	Hippocampal volume in subjects at clinical high-risk for psychosis: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2016, 71, 680-690.	2.9	38
184	Association of Neurocognition With Transition to Psychosis. JAMA Psychiatry, 2016, 73, 1239.	6.0	205
185	The Violent Content in Attenuated Psychotic Symptoms. Psychiatry Research, 2016, 242, 61-66.	1.7	14
186	Atypical functional connectivity in resting-state networks of individuals with 22q11.2 deletion syndrome: associations with neurocognitive and psychiatric functioning. Journal of Neurodevelopmental Disorders, 2016, 8, 2.	1.5	26
187	Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. Psychiatry Research - Neuroimaging, 2016, 254, 3-9.	0.9	8
188	Social cognition over time in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research, 2016, 171, 176-181.	1.1	55
189	A randomized placebo ontrolled lovastatin trial for neurobehavioral function in neurofibromatosis I. Annals of Clinical and Translational Neurology, 2016, 3, 266-279.	1.7	44
190	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. Schizophrenia Research, 2016, 172, 106-113.	1.1	20
191	Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 497-503.	1.6	60
192	Genetic contributions to circadian activity rhythm and sleep pattern phenotypes in pedigrees segregating for severe bipolar disorder. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E754-61.	3.3	77
193	Rare copy number variants and congenital heart defects in the 22q11.2 deletion syndrome. Human Genetics, 2016, 135, 273-285.	1.8	43
194	Resting state functional <scp>MRI</scp> reveals abnormal network connectivity in neurofibromatosis 1. Human Brain Mapping, 2015, 36, 4566-4581.	1.9	29
195	Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. BMC Psychiatry, 2015, 15, 276.	1.1	18
196	Perceptions of family criticism and warmth and their link to symptom expression in racially/ethnically diverse adolescents and young adults at clinical high risk for psychosis. Microbial Biotechnology, 2015, 9, 476-486.	0.9	10
197	North American Prodrome Longitudinal Study (NAPLS 2). Journal of Nervous and Mental Disease, 2015, 203, 328-335.	O.5	189
198	Altered Brain Structure-Function Relationships Underlie Executive Dysfunction in 22q11.2 Deletion Syndrome. Molecular Neuropsychiatry, 2015, 1, 235-246.	3.0	5

#	Article	IF	CITATIONS
199	Transcriptome Profiling of Peripheral Blood in 22q11.2 Deletion Syndrome Reveals Functional Pathways Related to Psychosis and Autism Spectrum Disorder. PLoS ONE, 2015, 10, e0132542.	1.1	40
200	Negative symptoms and impaired social functioning predict later psychosis in <scp>L</scp> atino youth at clinical high risk in the <scp>N</scp> orth <scp>A</scp> merican prodromal longitudinal studies consortium. Microbial Biotechnology, 2015, 9, 467-475.	0.9	26
201	Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion among Clinically High-Risk Youth Developing Psychotic Disorders. Molecular Neuropsychiatry, 2015, 1, 13-22.	3.0	27
202	Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. Psychiatry Research, 2015, 230, 878-884.	1.7	13
203	Early Detection of Psychosis: Recent Updates from Clinical High-Risk Research. Current Behavioral Neuroscience Reports, 2015, 2, 90-101.	0.6	3
204	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	6.0	196
205	Time Reproduction Performance Is Associated With Age and Working Memory in Highâ€Functioning Youth With Autism Spectrum Disorder. Autism Research, 2015, 8, 29-37.	2.1	20
206	Theory of mind, emotion recognition and social perception in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research: Cognition, 2015, 2, 133-139.	0.7	46
207	Contributions of Feature Binding During Encoding and Functional Connectivity of the Medial Temporal Lobe Structures to Episodic Memory Deficits Across the Prodromal and First-Episode Phases of Schizophrenia. Clinical Psychological Science, 2015, 3, 159-174.	2.4	21
208	Copy-Number Variation of the Glucose Transporter Gene SLC2A3 and Congenital Heart Defects in the 22q11.2 Deletion Syndrome. American Journal of Human Genetics, 2015, 96, 753-764.	2.6	62
209	Brain structure–function associations in multi-generational families genetically enriched for bipolar disorder. Brain, 2015, 138, 2087-2102.	3.7	33
210	Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. Human Brain Mapping, 2015, 36, 2558-2579.	1.9	63
211	Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. JAMA Psychiatry, 2015, 72, 882.	6.0	284
212	Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2015, 41, 1066-1075.	2.3	71
213	Severity of thought disorder predicts psychosis in persons at clinical high-risk. Schizophrenia Research, 2015, 169, 169-177.	1.1	43
214	Neural Substrates of Inhibitory Control Deficits in 22q11.2 Deletion Syndromeâ€. Cerebral Cortex, 2015, 25, 1069-1079.	1.6	16
215	Demographic correlates of attenuated positive psychotic symptoms. Schizophrenia Research, 2015, 166, 31-36.	1.1	17
216	Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk. Biological Psychiatry, 2015, 77, 147-157.	0.7	516

#	Article	IF	CITATIONS
217	Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project. Schizophrenia Bulletin, 2015, 41, 419-428.	2.3	195
218	Altered white matter microstructure is associated with social cognition and psychotic symptoms in 22q11.2 microdeletion syndrome. Frontiers in Behavioral Neuroscience, 2014, 8, 393.	1.0	52
219	Cortical Volume Alterations in Conduct Disordered Adolescents with and without Bipolar Disorder. Journal of Clinical Medicine, 2014, 3, 416-431.	1.0	10
220	Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Human Brain Mapping, 2014, 35, 2424-2434.	1.9	76
221	Multisystem Component Phenotypes of Bipolar Disorder for Genetic Investigations of Extended Pedigrees. JAMA Psychiatry, 2014, 71, 375.	6.0	87
222	Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2014, 171, 627-639.	4.0	645
223	Autism traits in the RASopathies. Journal of Medical Genetics, 2014, 51, 10-20.	1.5	134
224	The 22q11.2 Deletion Syndrome as a Window into Complex Neuropsychiatric Disorders Over the Lifespan. Biological Psychiatry, 2014, 75, 351-360.	0.7	167
225	Default mode network connectivity and reciprocal social behavior in 22q11.2 deletion syndrome. Social Cognitive and Affective Neuroscience, 2014, 9, 1261-1267.	1.5	68
226	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	1.1	696
227	Stress exposure and sensitivity in the clinical high-risk syndrome: Initial findings from the North American Prodrome Longitudinal Study (NAPLS). Schizophrenia Research, 2014, 160, 104-109.	1.1	66
228	Coping styles of individuals at clinical high risk for developing psychosis. Microbial Biotechnology, 2014, 8, 68-76.	0.9	47
229	Youth-caregiver Agreement on Clinical High-risk Symptoms of Psychosis. Journal of Abnormal Child Psychology, 2014, 42, 649-658.	3.5	7
230	Altered relationships between age and functional brain activation in adolescents at clinical high risk for psychosis. Psychiatry Research - Neuroimaging, 2014, 221, 21-29.	0.9	17
231	Reliability of functional magnetic resonance imaging activation during working memory in a multi-site study: Analysis from the North American Prodrome Longitudinal Study. NeuroImage, 2014, 97, 41-52.	2.1	48
232	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 439-447.	2.6	53
233	Corrigendum to "The Learning Disabilities Network (LeaDNet): Using Neurofibromatosis Type 1 [NF1] as a Paradigm for Translational Researchâ€: , 2013, 161, 236-236.		0
234	Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research, 2013, 148, 99-104.	1.1	33

#	Article	IF	CITATIONS
235	Structural abnormalities in cortical volume, thickness, and surface area in 22q11.2 microdeletion syndrome: Relationship with psychotic symptoms. NeuroImage: Clinical, 2013, 3, 405-415.	1.4	82
236	Converging levels of analysis on a genomic hotspot for psychosis: Insights from 22q11.2 Deletion Syndrome. Neuropharmacology, 2013, 68, 157-173.	2.0	27
237	Three-dimensional mapping of hippocampal and amygdalar structure in euthymic adults with bipolar disorder not treated with lithium. Psychiatry Research - Neuroimaging, 2013, 211, 195-201.	0.9	16
238	Reciprocal social behavior in youths with psychotic illness and those at clinical high risk. Development and Psychopathology, 2013, 25, 1187-1197.	1.4	21
239	Genetic Architecture of Declarative Memory. Neuroscientist, 2012, 18, 516-532.	2.6	13
240	Social cognition in 22q11.2 microdeletion syndrome: Relevance to psychosis?. Schizophrenia Research, 2012, 142, 99-107.	1.1	68
241	Deficits in Mental State Attributions in Individuals with 22q11.2 Deletion Syndrome (<scp>V</scp> eloâ€Cardioâ€Facial Syndrome). Autism Research, 2012, 5, 407-418.	2.1	34
242	The Voices Go, But the Song Remains the Same: How Can We Rescue Cognition in Early-Onset Schizophrenia?. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 464-466.	0.3	4
243	Recovery From an At-Risk State: Clinical and Functional Outcomes of Putatively Prodromal Youth Who Do Not Develop Psychosis. Schizophrenia Bulletin, 2012, 38, 1225-1233.	2.3	138
244	Social Cognition in Schizophrenia, Part 1: Performance Across Phase of Illness. Schizophrenia Bulletin, 2012, 38, 854-864.	2.3	354
245	Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: A preliminary study. Schizophrenia Research, 2012, 134, 1-9.	1.1	70
246	The Learning Disabilities Network (LeaDNet): Using neurofibromatosis type 1 (NF1) as a paradigm for translational research. American Journal of Medical Genetics, Part A, 2012, 158A, 2225-2232.	0.7	29
247	Processing Speed and Neurodevelopment in Adolescent-Onset Psychosis: Cognitive Slowing Predicts Social Function. Journal of Abnormal Child Psychology, 2012, 40, 645-654.	3.5	29
248	Trait impulsivity as an endophenotype for bipolar I disorder. Bipolar Disorders, 2012, 14, 565-570.	1.1	62
249	Hippocampal morphology in lithium and nonâ€lithiumâ€treated bipolar I disorder patients, nonâ€bipolar coâ€twins, and control twins. Human Brain Mapping, 2012, 33, 501-510.	1.9	58
250	Alterations in White Matter Microstructure in Neurofibromatosis-1. PLoS ONE, 2012, 7, e47854.	1.1	61
251	Thought Disorder and Communication Deviance as Predictors of Outcome in Youth at Clinical High Risk for Psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 669-680.	0.3	92
252	Clinical and Genetic High-Risk Paradigms: Converging Paths to Psychosis Meet in the Temporal Lobes. Biological Psychiatry, 2011, 69, 910-911.	0.7	9

#	Article	IF	CITATIONS
253	Psychosis risk screening with the Prodromal Questionnaire — Brief Version (PQ-B). Schizophrenia Research, 2011, 129, 42-46.	1.1	306
254	Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis. Schizophrenia Research, 2011, 130, 164-169.	1.1	37
255	Genetic influence on the working memory circuitry: Behavior, structure, function and extensions to illness. Behavioural Brain Research, 2011, 225, 610-622.	1.2	37
256	Response to De Nadai Letter. American Journal of Psychiatry, 2011, 168, 550-551.	4.0	0
257	Association of clinical symptoms and neurocognitive performance in bipolar disorder: a longitudinal study. Bipolar Disorders, 2011, 13, 118-123.	1.1	54
258	The impact of neurocognitive impairment on occupational recovery of clinically stable patients with bipolar disorder: a prospective study. Bipolar Disorders, 2011, 13, 323-333.	1.1	87
259	Response to the Letter to the Editor: "Clinical symptoms and neurocognitive performance: potential impact of substance use― Bipolar Disorders, 2011, 13, 435-436.	1.1	0
260	Mapping Corpus Callosum Morphology in Twin Pairs Discordant for Bipolar Disorder. Cerebral Cortex, 2011, 21, 2415-2424.	1.6	39
261	Integrity of emotional and motivational states during the prodromal, first-episode, and chronic phases of schizophrenia Journal of Abnormal Psychology, 2010, 119, 71-82.	2.0	33
262	Neurocognitive and Neuroimaging Predictors of Clinical Outcome in Bipolar Disorder. Current Psychiatry Reports, 2010, 12, 499-504.	2.1	38
263	Frontoâ€ŧemporal dysregulation in asymptomatic bipolar I patients: A paired associate functional MRI study. Human Brain Mapping, 2010, 31, 1041-1051.	1.9	37
264	The International Society for Bipolar Disorders–Battery for Assessment of Neurocognition (ISBDâ€BANC). Bipolar Disorders, 2010, 12, 351-363.	1.1	218
265	Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder. Bipolar Disorders, 2010, 12, 866-874.	1.1	29
266	Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13141-13146.	3.3	144
267	Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium <subtitle>Relationship to Family History and Conversion to Psychosis</subtitle> <alt-title>Neuropsychology of Prodrome to Psychosis</alt-title> . Archives of General Psychiatry, 2010, 67, 578.	13.8	390
268	Identification and Treatment of a Pineal Region Tumor in an Adolescent With Prodromal Psychotic Symptoms. American Journal of Psychiatry, 2010, 167, 1033-1037.	4.0	28
269	Markers of Basal Ganglia Dysfunction and Conversion to Psychosis: Neurocognitive Deficits and Dyskinesias in the Prodromal Period. Biological Psychiatry, 2010, 68, 93-99.	0.7	86
270	Language network dysfunction as a predictor of outcome in youth at clinical high risk for psychosis. Schizophrenia Research, 2010, 116, 173-183.	1.1	98

#	Article	IF	CITATIONS
271	Predicting the longitudinal effects of the family environment on prodromal symptoms and functioning in patients at-risk for psychosis. Schizophrenia Research, 2010, 118, 69-75.	1.1	70
272	Striatal volumes and dyskinetic movements in youth at high-risk for psychosis. Schizophrenia Research, 2010, 123, 68-70.	1.1	47
273	Alterations in Midline Cortical Thickness and Gyrification Patterns Mapped in Children with 22q11.2 Deletions. Cerebral Cortex, 2009, 19, 115-126.	1.6	75
274	Symptomatic and functional correlates of regional brain physiology during working memory processing in patients with recent onset schizophrenia. Psychiatry Research - Neuroimaging, 2009, 173, 177-182.	0.9	14
275	Exploring Predictors of Outcome in the Psychosis Prodrome: Implications for Early Identification and Intervention. Neuropsychology Review, 2009, 19, 280-293.	2.5	58
276	Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disorders, 2009, 11, 33-40.	1.1	125
277	Frontoâ€temporal dysregulation in remitted bipolar patients: an fMRI delayedâ€nonâ€matchâ€toâ€sample (DNM study. Bipolar Disorders, 2009, 11, 351-360.	S) 1.1	40
278	Impulsivity, risk taking, alcohol abuse, and bipolar disorder: response to Thomas Richardson. Bipolar Disorders, 2009, 11, 556-557.	1.1	0
279	Obstetric complications and risk for conversion to psychosis among individuals at high clinical risk. Microbial Biotechnology, 2009, 3, 226-230.	0.9	11
280	White Matter Integrity and Prediction of Social and Role Functioning in Subjects at Ultra-High Risk for Psychosis. Biological Psychiatry, 2009, 66, 562-569.	0.7	209
281	Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: A longitudinal study. Schizophrenia Research, 2009, 107, 198-205.	1.1	70
282	Obsessive compulsive symptoms in the psychosis prodrome: Correlates of clinical and functional outcome. Schizophrenia Research, 2009, 108, 170-175.	1.1	93
283	Re-evaluating dorsolateral prefrontal cortex activation during working memory in schizophrenia. Schizophrenia Research, 2009, 108, 143-150.	1.1	89
284	Paternal age as a risk factor for schizophrenia: How important is it?. Schizophrenia Research, 2009, 114, 1-5.	1.1	76
285	Elucidating a Magnetic Resonance Imaging-Based Neuroanatomic Biomarker for Psychosis: Classification Analysis Using Probabilistic Brain Atlas and Machine Learning Algorithms. Biological Psychiatry, 2009, 66, 1055-1060.	0.7	134
286	Methodological Issues in Molecular Genetic Studies of Mental Disorders. Annual Review of Clinical Psychology, 2009, 5, 49-69.	6.3	12
287	Altered Hippocampal Morphology in Unmedicated Patients with Major Depressive Illness. ASN Neuro, 2009, 1, AN20090026.	1.5	52
288	Parent attitudes and parent adolescent interaction in families of youth at risk for psychosis and with recentâ€onset psychotic symptoms. Microbial Biotechnology, 2008, 2, 268-276.	0.9	31

#	Article	IF	CITATIONS
289	Fronto-limbic circuitry in euthymic bipolar disorder: Evidence for prefrontal hyperactivation. Psychiatry Research - Neuroimaging, 2008, 164, 106-113.	0.9	72
290	Remember and know judgments during recognition in chronic schizophrenia. Schizophrenia Research, 2008, 100, 181-190.	1.1	49
291	Gender differences in symptoms, functioning and social support in patients at ultra-high risk for developing a psychotic disorder. Schizophrenia Research, 2008, 104, 237-245.	1.1	83
292	Reply: Lithium and Increased Cortical Gray Matter—More Tissue or More Water?. Biological Psychiatry, 2008, 63, e19.	0.7	2
293	Diffusion Tensor Imaging of the Superior Longitudinal Fasciculus and Working Memory in Recent-Onset Schizophrenia. Biological Psychiatry, 2008, 63, 512-518.	0.7	308
294	Three-Dimensional Mapping of Hippocampal Anatomy in Adolescents With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 515-525.	0.3	55
295	A relationship between neurocognitive impairment and functional impairment in bipolar disorder: A pilot study. Psychiatry Research, 2008, 157, 289-293.	1.7	60
296	Neural phenotypes of common and rare genetic variants. Biological Psychology, 2008, 79, 43-57.	1.1	11
297	Three-Dimensional Mapping of Hippocampal Anatomy in Unmedicated and Lithium-Treated Patients with Bipolar Disorder. Neuropsychopharmacology, 2008, 33, 1229-1238.	2.8	148
298	Mapping Cortical Thickness in Children with 22q11.2 Deletions. Cerebral Cortex, 2007, 17, 1889-1898.	1.6	88
299	Preliminary Findings for Two New Measures of Social and Role Functioning in the Prodromal Phase of Schizophrenia. Schizophrenia Bulletin, 2007, 33, 688-702.	2.3	484
300	The Course of Neurocognition and Social Functioning in Individuals at Ultra High Risk for Psychosis. Schizophrenia Bulletin, 2007, 33, 772-781.	2.3	139
301	Ecological assessment of executive dysfunction in the psychosis prodrome: A pilot study. Schizophrenia Research, 2007, 93, 350-354.	1.1	27
302	Greater Cortical Gray Matter Density in Lithium-Treated Patients with Bipolar Disorder. Biological Psychiatry, 2007, 62, 7-16.	0.7	271
303	The Neurocognitive Signature of Psychotic Bipolar Disorder. Biological Psychiatry, 2007, 62, 910-916.	0.7	210
304	Cortical mapping of genotype–phenotype relationships in schizophrenia. Human Brain Mapping, 2007, 28, 519-532.	1.9	23
305	Psychoeducational multiâ€family group treatment with adolescents at high risk for developing psychosis. Microbial Biotechnology, 2007, 1, 325-332.	0.9	37
306	Evidence for disruption in prefrontal cortical functions in juvenile bipolar disorder. Bipolar Disorders, 2007, 9, 145-159.	1.1	45

#	Article	IF	CITATIONS
307	Neurocognitive Findings in Bipolar Disorder. Medical Psychiatry, 2007, , 251-274.	0.2	1
308	Positive family environment predicts improvement in symptoms and social functioning among adolescents at imminent risk for onset of psychosis. Schizophrenia Research, 2006, 81, 269-275.	1.1	128
309	Neurocognitive performance and functional disability in the psychosis prodrome. Schizophrenia Research, 2006, 84, 100-111.	1.1	232
310	Patterns of memory impairment in bipolar disorder and unipolar major depression. Psychiatry Research, 2006, 142, 139-150.	1.7	140
311	Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia. Psychological Medicine, 2006, 36, 1085-1095.	2.7	30
312	Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disorders, 2006, 8, 117-123.	1.1	154
313	Reduced educational attainment in bipolar disorder. Journal of Affective Disorders, 2006, 92, 309-312.	2.0	59
314	Endophenotypes for psychiatric disorders: ready for primetime?. Trends in Genetics, 2006, 22, 306-313.	2.9	193
315	Sources of declarative memory impairment in bipolar disorder: Mnemonic processes and clinical features. Journal of Psychiatric Research, 2006, 40, 47-58.	1.5	70
316	A multilevel analysis of cognitive dysfunction and psychopathology associated with chromosome 22q11.2 deletion syndrome in children. Development and Psychopathology, 2005, 17, 753-84.	1.4	73
317	Declarative memory impairment in pediatric bipolar disorder. Bipolar Disorders, 2005, 7, 546-554.	1.1	57
318	Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Human Brain Mapping, 2005, 25, 60-69.	1.9	547
319	Common Substrates of Dysphoria in Stimulant Drug Abuse and Primary Depression: Therapeutic Targets. International Review of Neurobiology, 2005, 65, 117-145.	0.9	3
320	The Psychosis Prodrome in Adolescent Patients Viewed Through the Lens of DSM-IV. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 434-451.	0.7	115
321	Visuospatial and Numerical Cognitive Deficits in Children with Chromosome 22Q11.2 Deletion Syndrome. Cortex, 2005, 41, 145-155.	1.1	131
322	Attention deficits in bipolar disorder: a comparison based on the Continuous Performance Test. Neuroscience Letters, 2005, 379, 122-126.	1.0	39
323	The prodromal questionnaire (PQ): Preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophrenia Research, 2005, 79, 117-125.	1.1	259
324	Effects of Comt Genotype on Behavioral Symptomatology in the 22q11.2 Deletion Syndrome. Child Neuropsychology, 2005, 11, 109-117.	0.8	34

#	Article	IF	CITATIONS
325	The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophrenia Research, 2005, 79, 117-25.	1.1	88
326	Regional Brain Abnormalities in 22q11.2 Deletion Syndrome: Association With Cognitive Abilities and Behavioral Symptoms. Neurocase, 2004, 10, 198-206.	0.2	30
327	Effects of a Functional COMT Polymorphism on Prefrontal Cognitive Function in Patients With 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2004, 161, 1700-1702.	4.0	122
328	The feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder. Bipolar Disorders, 2004, 6, 171-182.	1.1	244
329	Why genetic investigation of psychiatric disorders is so difficult. Current Opinion in Genetics and Development, 2004, 14, 280-286.	1.5	45
330	Early and Late Neurodevelopmental Influences in the Prodrome to Schizophrenia: Contributions of Genes, Environment, and Their Interactions. Schizophrenia Bulletin, 2003, 29, 653-669.	2.3	238
331	A Prospective Study of Childhood Neurocognitive Functioning in Schizophrenic Patients and Their Siblings. American Journal of Psychiatry, 2003, 160, 2060-2062.	4.0	186
332	Catatonia isn't ready for a unified theory. Behavioral and Brain Sciences, 2002, 25, 579-580.	0.4	1
333	Cognitive development in VCFS. Progress in Pediatric Cardiology, 2002, 15, 109-117.	0.2	45
334	Williams syndrome cognitive profile also characterizes Velocardiofacial/DiGeorge syndrome. American Journal of Medical Genetics Part A, 2002, 114, 689-692.	2.4	18
335	The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disorders, 2001, 3, 106-150.	1.1	479
336	The Neurocognitive Phenotype of the 22Q11.2 Deletion Syndrome: Selective Deficit in Visual-Spatial Memory. Journal of Clinical and Experimental Neuropsychology, 2001, 23, 447-464.	0.8	201
337	A Prospective Cohort Study of Childhood Behavioral Deviance and Language Abnormalities as Predictors of Adult Schizophrenia. Schizophrenia Bulletin, 2000, 26, 395-410.	2.3	130
338	Childhood Cognitive Functioning in Schizophrenia Patients and Their Unaffected Siblings: A Prospective Cohort Study. Schizophrenia Bulletin, 2000, 26, 379-393.	2.3	211
339	A prospective cohort study of neurodevelopmental processes in the genesis and epigenesis of schizophrenia. Development and Psychopathology, 1999, 11, 467-485.	1.4	74
340	Personality Pathology and Time to Remission in Depressed Outpatients Treated with Interpersonal Psychotherapy. Journal of Personality Disorders, 1996, 10, 164-173.	0.8	9
341	Neurocognitive findings in bipolar disorder: an update. , 0, , 169-190.		0
342	Systems Analysis of the 22q11.2 Microdeletion Syndrome Converges on a Mitochondrial Interactome Necessary for Synapse Function and Behavior. SSRN Electronic Journal, 0, , .	0.4	1